These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 32909178)

  • 41. Vasculoprotection as a Convergent, Multi-Targeted Mechanism of Anti-AD Therapeutics and Interventions.
    Bhat NR
    J Alzheimers Dis; 2015; 46(3):581-91. PubMed ID: 26402511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Five-year incidence of common comorbidities, such as hypertension, dyslipidemia, diabetes mellitus, cardiovascular disease, cerebrovascular disease and cancer, in older Japanese patients with rheumatoid arthritis.
    Mochizuki T; Ikari K; Yano K; Okazaki K
    Geriatr Gerontol Int; 2019 Jul; 19(7):577-581. PubMed ID: 30950139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of stress on cardiovascular disease and Alzheimer's disease: Physical exercise as a counteract measure.
    Sanchis-Soler G; Tortosa-Martínez J; Manchado-Lopez C; Cortell-Tormo JM
    Int Rev Neurobiol; 2020; 152():157-193. PubMed ID: 32450995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical approach to the inflammatory etiology of cardiovascular diseases.
    Ruscica M; Corsini A; Ferri N; Banach M; Sirtori CR
    Pharmacol Res; 2020 Sep; 159():104916. PubMed ID: 32445957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Preventive effects of curcumin and resveratrol in Alzheimer’s disease].
    Tęcza P; Żylińska L
    Przegl Lek; 2016; 73(5):320-3. PubMed ID: 29630139
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Arresting cardiovascular disease progression. Early treatment may counteract high risk.
    Ram CV; Vergne-Marini P
    Postgrad Med; 2004 Aug; 116(2):45-8. PubMed ID: 15323153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease.
    Vu M; Koponen M; Taipale H; Tanskanen A; Tiihonen J; Kettunen R; Hartikainen S; Tolppanen AM
    Int J Cardiol; 2020 Feb; 300():221-225. PubMed ID: 31810814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of natural products for the treatment of Alzheimer's disease.
    Noori T; Dehpour AR; Sureda A; Sobarzo-Sanchez E; Shirooie S
    Eur J Pharmacol; 2021 May; 898():173974. PubMed ID: 33652057
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects.
    Keshava HB; Mowla A; Heinberg LJ; Schauer PR; Brethauer SA; Aminian A
    Med Hypotheses; 2017 Jul; 104():4-9. PubMed ID: 28673587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cholesterol, statins, and dementia: what the cardiologist should know.
    Wanamaker BL; Swiger KJ; Blumenthal RS; Martin SS
    Clin Cardiol; 2015 Apr; 38(4):243-50. PubMed ID: 25869997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carotid artery ultrasound and echocardiography testing to lower the prevalence of Alzheimer's disease.
    de la Torre JC
    J Stroke Cerebrovasc Dis; 2009; 18(4):319-28. PubMed ID: 19560690
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular disease risk factors and progression of Alzheimer's disease.
    Abellan van Kan G; Rolland Y; Nourhashémi F; Coley N; Andrieu S; Vellas B
    Dement Geriatr Cogn Disord; 2009; 27(3):240-6. PubMed ID: 19246908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?
    Ahn KC; Learman CR; Baker GB; Weaver CL; Chung PS; Kim HG; Song MS
    J Korean Med Sci; 2019 Dec; 34(46):e297. PubMed ID: 31779058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk and protective factors for sporadic Alzheimer's disease.
    Stozická Z; Zilka N; Novák M
    Acta Virol; 2007; 51(4):205-22. PubMed ID: 18197729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes.
    Zhang Y; Vitry A; Caughey G; Roughead EE; Ryan P; Gilbert A; Shakib S; McDermott R
    Diabetes Res Clin Pract; 2011 Jan; 91(1):115-20. PubMed ID: 21067836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives.
    de Castro AA; da Cunha EFF; Pereira AF; Soares FV; Leal DHS; Kuca K; Ramalho TC
    Curr Alzheimer Res; 2018; 15(12):1161-1178. PubMed ID: 30101709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer's disease--a translational perspective.
    Apetz N; Munch G; Govindaraghavan S; Gyengesi E
    CNS Neurol Disord Drug Targets; 2014; 13(7):1175-91. PubMed ID: 25230232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.